Who and when should we screen for prostate cancer? Interviews with key opinion leaders

Sigrid Carlsson; Michael Leapman; Peter Carroll; Fritz Schröder; Peter C Albertsen; Dragan Ilic; Michael Barry; Dominick L Frosch; Andrew Vickers

doi:10.1186/s12916-015-0526-x

Who and when should we screen for prostate cancer? Interviews with key opinion leaders

BMC Med. 2015 Nov 27:13:288. doi: 10.1186/s12916-015-0526-x.

Authors

Sigrid Carlsson¹, Michael Leapman², Peter Carroll³, Fritz Schröder⁴, Peter C Albertsen⁵, Dragan Ilic⁶, Michael Barry⁷, Dominick L Frosch⁸, Andrew Vickers⁹

Affiliations

¹ Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, 10017, NY, USA. carlssos@mskcc.org
² Department of Urology, University of California, San Francisco, CA, USA. michael.leapman@ucsf.edu.
³ Department of Urology, University of California, San Francisco, CA, USA. peter.carroll@ucsf.edu.
⁴ Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands. secr.schroder@erasmusmc.nl.
⁵ University of Connecticut Health Center, 263 Farmington Avenue, Farmington, 06030, CT, USA. albertsen@uchc.edu.
⁶ Department of Epidemiology & Preventive Medicine, Monash University, Level 6, The Alfred Centre, 99 Commercial Rd, Melbourne, VIC, 3004, Australia. dragan.ilic@monash.edu.
⁷ The Informed Medical Decisions Foundation, Boston, MA, USA. dominick.frosch@moore.org.
⁸ Gordon and Betty Moore Foundation, Palo Alto, CA & Department of Medicine, University of California, Los Angeles, USA. mbarry@healthwise.org.
⁹ Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, 10017, NY, USA. vickersa@mskcc.org.

Abstract

Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine's 'Spotlight on Prostate Cancer' article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world's key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts' views and give their own personal opinions on PSA screening.

Publication types

Interview
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Early Detection of Cancer
Humans
Male
Middle Aged
Prostate-Specific Antigen / metabolism*
Prostatic Neoplasms / diagnosis*

Substances

Prostate-Specific Antigen

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States